Inotek Pharmaceuticals Announces Participation in Fireside Chat at JMP Securities 2016 Life Sciences Conference

LEXINGTON, Mass.–(BUSINESS WIRE)– Inotek
Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of therapies for ocular diseases, today announced that
David P. Southwell, President and Chief Executive Officer of Inotek,
will participate in a fireside chat at the JMP Securities 2016 Life
Sciences Conference. The fireside chat will take place at the St. Regis
New York on Wednesday, June 22, 2016 at 9:00 am EST.

About Inotek Pharmaceuticals Corporation
Inotek
Pharmaceuticals is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of therapies for
glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson,
is a first-in-class selective adenosine mimetic currently in Phase 3
development. Trabodenoson was developed in Inotek’s
laboratories and is designed to restore the eye’s natural pressure
control mechanism. Additionally, the Company is evaluating the potential
for selective adenosine mimetics to address optic neuropathies and other
degenerative retinal diseases. For more information, please visit www.inotekpharma.com.

Forward-Looking Statements
This press release contains
forward-looking statements, which are subject to substantial risks,
uncertainties and assumptions. These forward-looking statements often
include words such as “believe,” “expect,” “anticipate,” “intend,”
“plan,” “estimate,” “seek,” “will,” “may” or similar expressions.
Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of the
date made, and the Company undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160616005349/en/